Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc. compare based on key financial metrics to determine which better meets your investment needs.

About Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. In addition, it conducts preclinical studies for APL-9099, a treatment targeting the neonatal Fc receptor, or FcRn, which has the potential to be a first-in-class gene editing treatment for future target indications with one-time dosing; and developing other programs with its proprietary in-house capabilities and under its Beam collaboration. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics, Inc. focused on the use of Beam’s base editing technology to discover new treatments for complement-driven diseases. Apellis Pharmaceuticals, Inc. was incorporated in 2009 and is headquartered in Waltham, Massachusetts.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering novel medicines for rare diseases in the United States and internationally. The company’s commercial product and product candidates consist of Galafold, an orally administered monotherapy for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; Pombiliti + Opfolda, a novel two-component treatment program for adults living with late-onset Pompe disease; and DMX-200, a small molecule inhibitor of the chemokine receptor 2 that is in a pivotal Phase 3 study for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease. It has collaboration and license agreement with GlaxoSmithKline to develop and commercialize Galafold; and Dimerix Limited for the commercialization of DMX-200 for the treatment of FSGS and other indications. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Latest Biotechnology and Apellis Pharmaceuticals, Inc., Amicus Therapeutics, Inc. Stock News

As of February 25, 2026, Apellis Pharmaceuticals, Inc. had a $2.7 billion market capitalization, compared to the Biotechnology median of $283.1 million. Apellis Pharmaceuticals, Inc.’s stock is down 12.8% in 2026, down 3.9% in the previous five trading days and down 21.85% in the past year.

Currently, Apellis Pharmaceuticals, Inc.’s price-earnings ratio is 124.5. Apellis Pharmaceuticals, Inc.’s trailing 12-month revenue is $1.0 billion with a 2.2% net profit margin. Year-over-year quarterly sales growth most recently was -5.9%. Analysts expect adjusted earnings to reach $-1.139 per share for the current fiscal year. Apellis Pharmaceuticals, Inc. does not currently pay a dividend.

As of February 25, 2026, Amicus Therapeutics, Inc. had a $4.5 billion market cap, putting it in the 66th percentile of all stocks. Amicus Therapeutics, Inc.’s stock is up 0.7% in 2026, down 0.1% in the previous five trading days and up 53.53% in the past year.

Currently, Amicus Therapeutics, Inc. does not have a price-earnings ratio. Amicus Therapeutics, Inc.’s trailing 12-month revenue is $634.2 million with a -4.3% net profit margin. Year-over-year quarterly sales growth most recently was 23.7%. Analysts expect adjusted earnings to reach $0.647 per share for the current fiscal year. Amicus Therapeutics, Inc. does not currently pay a dividend.

How We Compare Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc. Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc.’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc. Stock Value Grades

Company	Ticker	Value
Apellis Pharmaceuticals, Inc.	APLS	F
Amicus Therapeutics, Inc.	FOLD	F

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Apellis Pharmaceuticals, Inc. has a Value Score of 8, which is Ultra Expensive. Amicus Therapeutics, Inc. has a Value Score of 4, which is Ultra Expensive.

The Value Stock Winner: No Clear Winner

Neither Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. is the better investment when it comes to value.

Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc. Growth Grades

Company	Ticker	Growth
Apellis Pharmaceuticals, Inc.	APLS	F
Amicus Therapeutics, Inc.	FOLD	D

The foundation of growth investing is seeking out stocks of companies exhibiting strong, consistent and prolonged growth that is expected to continue into the future.

In order to compute the growth score and assign it a letter grade, the percentile ranks for each of three components‐consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations‐must be determined. These three rank figures are added together, and the sum is ranked against the entire stock universe to arrive at a company’s Growth Score to create an equal distribution of grades.

The companies in the bottom 20% of the stock universe receive Growth Grades of F, considered to be very weak, while those in the top 20% receive A grades, which are considered very strong.

Apellis Pharmaceuticals, Inc. has a Growth Score of 20, which is Very Weak. Amicus Therapeutics, Inc. has a Growth Score of 30, which is Weak.

The Growth Stock Winner: No Clear Winner

Neither Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. has a high enough Growth Grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. is the better investment when it comes to sustainable growth.

Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc.’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Apellis Pharmaceuticals, Inc.	APLS	C
Amicus Therapeutics, Inc.	FOLD	D

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Apellis Pharmaceuticals, Inc. has a Earnings Estimate Score of 55, which is Neutral. Amicus Therapeutics, Inc. has a Earnings Estimate Score of 37, which is Negative.

The Earnings Estimate Revisions Stock Winner: No Clear Winner

Neither Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. has an Earnings Estimate Revisions Grade that could be considered a “winner.” Investors considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolios. It’s important to look at a wide range of financial metrics in order to determine if Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. is the better investment when it comes to estimate revisions.

Other Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc. Grades

In addition to Growth, Estimate Revisions and Value, A+ Investor also provides grades for Momentum and Quality.

Momentum grades help uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc. pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Apellis Pharmaceuticals, Inc., Amicus Therapeutics or Inc. Stock?

Overall, Apellis Pharmaceuticals, Inc. stock has a Value Score of 8, Growth Score of 20 and Estimate Revisions Score of 55.

Amicus Therapeutics, Inc. stock has a Value Score of 4, Growth Score of 30 and Estimate Revisions Score of 37.

Comparing Apellis Pharmaceuticals, Inc., Amicus Therapeutics and Inc.’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.